Background: Genomic analysis of plasma cell-free DNA is transforming lung cancer care; however, available assays are limited by cost, turnaround time, and imperfect accuracy. Here, we study amplicon-based plasma next-generation sequencing (NGS), rather than hybrid-capture-based plasma NGS, hypothesizing this would allow sensitive detection and monitoring of driver and resistance mutations in advanced non-small cell lung cancer (NSCLC).
Introduction
Genotype-directed treatment of non-small cell lung cancer (NSCLC) has led to dramatic improvement in the management of selected patients harboring a targetable oncogenic driver [1] . The limited availability of tissue to test an increasing number of potentially actionable genotypes and a better understanding of druggable mechanisms of resistance [2] have created a need for a rapid, repeatable and noninvasive access to the tumor biology throughout treatment. Genotyping of plasma cell-free DNA (cfDNA) is already an established diagnostic tool that can guide rapid initiation of TKI therapy in EGFR-mutant NSCLC [3, 4] , avoiding some invasive biopsies. However, the most established assays are digital PCR-based, detecting mutations at only a single site in a predefined gene.
Unlike digital PCR plasma genotyping, next-generation sequencing (NGS) of cfDNA has the potential to more broadly assess the molecular profile of the tumor. Hybrid capture-based NGS of plasma cfDNA has already been well evaluated in NSCLC [5] [6] [7] . While this technical approach permits sequencing of dozens of genes and detection of complex variants, including rearrangements, concordance with matched tumor genotyping has been suboptimal in some series [5, 6] . Amplicon-based NGS is a well-established alternate technology, which uses target gene enrichment by PCR with a set of primers for exons or hotspots of selected genes [8] , and is the basis for the tumor NGS assay that recently received approval by the US FDA (Oncomine TM Dx Target, ThermoFisher). While this technology is less well studied for NGS of cfDNA, where the levels of input DNA (and tumor fraction) are usually very low, we hypothesized barcoded amplicon-based NGS would provide excellent sensitivity with limited sequencing artifact, and would represent a compelling alternative to hybrid capture-based plasma NGS.
Methods
Patients were identified with stage IIIB/IV, progressive NSCLC harboring a known tumor genotype and consented for plasma collection as part of two ongoing correlative studies at our institution. Plasma was collected for analysis before receipt of targeted therapy; when feasible, plasma was also collected at the initial toxicity evaluation and with restaging scans until development of resistance. We first studied a cohort of 30 patients with EGFR-mutant NSCLC and T790M-positive resistance receiving osimertinib; upon successful proof of principle, we then additionally studied a cohort of 16 patients harboring other rare targetable genotypes, totaling 168 time points from 46 subjects. Plasma analyses were carried out blinded to clinical information such as tumor genotype. Sensitivity and specificity for plasma droplet digital PCR (ddPCR) and plasma NGS assays were calculated using clinically carried out tumor genotyping as reference standard; tumor genotyping was carried out using hybridcapture NGS whenever possible [9] . Concordance of variant allelic fraction (AF) between plasma ddPCR and NGS was calculated using Kendall concordance coefficient.
Droplet digital PCR
Plasma genotyping using ddPCR was carried out for all cases with EGFRmutant NSCLC, as well as to validate selected non-EGFR hotspot mutations based on assay availability (e.g. KRAS, PIK3CA, BRAF mutations). ddPCR was carried out at the Belfer Center for Applied Cancer Science as described previously [3] . Remaining aliquots of plasma were allocated for plasma NGS, requiring a minimum of 1-2 mL of plasma or a corresponding quantity of extracted cfDNA.
Plasma NGS
Amplicon-based plasma NGS was carried out by Inivata (Morrisville, NC), using InVision TM , an enhanced version of TAm-Seq technology, based on methods previously described [10] [11] [12] . Thirty-six cancerrelated genes were sequenced using gene-specific primers designed to hotspots and entire coding regions of interest (supplementary Figure S1 , available at Annals of Oncology online). Extracted cfDNA is first quantified by digital PCR targeting a 108 bp region of the ribonuclease P/MRP subunit p30 (RPP30) gene [13] . Next generation sequencing libraries are then prepared from 2000 to 16 000 amplifiable copies of the genome (6.6 to 53 ng of amplifiable DNA) using a two-step PCR amplification process incorporating replicate and patient-specific barcodes and Illumina sequencing adaptors. In the first step PCR reaction, amplicons ranging from 73 to 155 bp are generated which were designed and optimized for the DNA fragment size found in circulation. Each sample is analyzed multiple times allowing the identification of false-positive and true-positive calls [10, 12] . After further clean-up using SPRI beads, samples are quantified and pooled to generate a normalized library of 12 nM. About 1.8 pM libraries are sequenced on the Illumina NextSeq with 5% PhiX added to monitor sequencing performance. A minimum Phred quality score of 30 for each base was required for inclusion in the analytics. Sequencing files were analyzed using Inivata's proprietary Somatic Mutation Analysis (ISoMA) pipeline.
In a subset of cases known to harbor oncogenic fusions, a separate aliquot of plasma cfDNA was tested using a novel technology designed to identify ALK and ROS1 breakpoints. The novel PCR-based assay has been designed to capture all major EML4-ALK variants in NSCLC, encompassing 95% of variants found in COSMIC (version 78). The panel also captures 90% of ROS1 fusions in NSCLC as described in the COSMIC database and identifies the breakpoints occurring between CD74-ROS1, SLC34A2-ROS1, SDC4-ROS1 and EZR-ROS1. The ALK and ROS1 assay covers 50 kb of intronic and exonic sequences, allowing the identification of precise DNA breakpoints in regions that are frequently re-arranged. Libraries were prepared and sequenced on the Illumina NextSeq 500 as described above.
Sequencing files were analyzed using Inivata's proprietary FUSP pipeline, which identifies specific DNA sequences brought together creating the fusions outlined above.
Results

Detecting known EGFR mutations
Using tissue genotyping as a reference standard, and ddPCR for orthogonal validation, sensitivity of plasma NGS was analyzed across 30 cases with EGFR-mutant NSCLC and acquired T790M. Sensitivity for detection of the driver EGFR mutation was 100% (30/30) with plasma NGS and 87% (26/30) for plasma ddPCR (P ¼ 0.11; 10/11 L858R, 16/19 exon 19 deletion). Sensitivity for the detection of T790M was 77% (23/30) for plasma NGS and 80% (24/30) for ddPCR. Discordance was only seen at low AF, below 1.1% ( Figure 1A ), where plasma NGS detected four driver mutations missed with ddPCR. Two T790M mutations detected with ddPCR and not with NGS were, retrospectively, below our ddPCR threshold for clinical reporting and could have been false positives (supplementary Figure S2 , available at Annals of Oncology online). Quantitative concordance of AF between NGS and ddPCR was excellent across 120 variants (from 80 specimens) positive for an EGFR mutation with both assays (R 2 ¼ 0.95, Figure 1B ).
Detection of rare variants and fusion genes
Studying nine cases with known ALK or ROS1 fusions, sensitivity of plasma NGS was 89% (6/7 EML4-ALK, 2/2 CD74-ROS1; Figure 1C and D); the one missed ALK case was the single patient studied with stage IIIB disease. Studying six cases with other mutations in the kinase domain (two MET splice mutation, three BRAF mutations and one HER2 exon 20 insertion), four were correctly identified ( Figure 1C ). Two cases of BRAF V600E in stage IV patients were undetectable with plasma NGS, and additionally were found to be undetectable on ddPCR. Interestingly one patient with a BRAF V600E mutation on tumor genotyping (RT-PCR) instead had a KRAS G12D mutation detected on plasma NGS (0.2% AF); this patient was a heavy smoker who did not respond to BRAF inhibitor therapy.
Specificity across other non-driver variants
To study specificity, we studied 19 cases with tumor NGS available (8 pre-osimertinib, 5 post-osimertinib and 6 pre-treatment specimens with other rare genotypes). For this analysis, we excluded each patient's driver oncogene, to avoid acquired resistance mutations, and limited our analysis to genes covered by both tissue and plasma NGS panels. Composite specificity-by-gene was 99.5% (Table 1) . First, one PIK3CA E545K mutation was found on plasma NGS at low AF (0.6%) but not in tumor; the mutation was confirmed in cfDNA by plasma ddPCR at the same AF (0.6%). Second, three point mutations in CTNNB1 were found at low AF (S37F 0.3%, S45C 1% and S45F 0.7%) on plasma NGS following osimertinib; corresponding tissue NGS did not reveal these, though tumor content may have been suboptimal (TP53 H193R mutation was found at 10% in tissue versus 30% in plasma). Third, an IDH1 R132H mutation was detected at low AF (0.3%) on plasma NGS but not in the corresponding tumor NGS; this variant recurred at multiple timepoints at a stable AF in this patient's cfDNA, suspicious for clonal hematopoiesis (supplementary Figure S3 , available at Annals of Oncology online) [14] .
Detection of resistance mechanisms using plasma NGS
We studied resistance in 25 osimertinib-treated subjects with detectable EGFR driver mutations with plasma NGS at the time of resistance. Fifteen patients (60%) lost T790M at resistance (Table 2) , and four of them had a non-EGFR resistance mutation identified: one PIK3CA E545K mutation (0.13% AF), two BRAF V600E mutations (12.5% AF, 0.4% AF) and one KRAS G12S mutation (0.2% AF). Gene amplifications were also detected at resistance in four patients (Figure 2 ): two HER2 amplifications (one occurring concomitantly with BRAF V600E), one MET amplification and one FGFR1 amplification. Ten patients maintained EGFR T790M at resistance, eight of whom acquired a tertiary EGFR C797S resistance mutation. In three patients, two C797S variants (c.2889T>A and c.2390G>C) were present at resistance at different AF ( Table 2) . One of these three patients additionally acquired a novel EGFR Q791P mutation (2.6% AF; supplementary Figure S4 , available at Annals of Oncology online). This mutation was confirmed in cfDNA using another amplicon-based NGS approach (QIAseq DNA Targeted Lung Panel, Qiagen; 2% AF). Interestingly, two patients with maintained T790M additionally acquired canonical KRAS mutations (KRAS G13D 0.2% AF; KRAS Q61K 2.8% AF). Limited to non-driver variants covered by the NGS panel (supplementary Figure S1 , available at Annals of Oncology online), 3 plasma NGS-positive/ tissue NGS-negative discordant results were seen (indicated in bold, 3/684 genes sequenced, specificity 99.6%). Resistance genotyping was also piloted in seven specimens from patients with rare genotypes treated with various TKIs (supplementary Table S1 , available at Annals of Oncology online). A mechanism of resistance could only be detected in one ALK-positive case (ALK C1156Y, 0.55% AF) after treatment with crizotinib. One ROS1 G2032R acquired resistance mutation, detected in tissue NGS in a ROS1 case after crizotinib, was not detected in plasma.
Early detection of resistance through serial plasma NGS
At least 3 serial plasma specimens (up to 8) were studied for 25 subjects treated with osimertinib, to pilot the early detection of resistance mechanisms. In four cases, a competing resistance mutation (KRAS Q61K, 2 BRAF V600E, PIK3CA E545K) could be detected pretreatment by plasma NGS. In these four cases, a complete and rapid clearance of the T790M clone was seen without immediate plasma clearance of the driver EGFR mutation (Figure 2) . No cases of EGFR C797S could be detected pre-osimertinib, though monitoring multiple timepoints on therapy revealed this mutation can be seen multiple months before clinical progression (Figure 2 ).
Discussion
In this blinded clinical validation, we demonstrate the ability of amplicon-based plasma NGS to sensitively detect a wide range of . In one patient (F), plasma NGS could also detect a competing KRAS Q61K mutation at low AF at baseline that with increased AF at resistance. [15] . The first generation of the TamSeq technology was developed by Forshew et al. on a dilution series of circulating DNA containing increasing frequencies of a rare allele, using a 48-primer set covering coding regions and hotspots in 6 genes. It was then validated using plasma samples from metastatic ovarian cancer patents. This foundational work reported high sensitivity, specificity and quantitative concordance with digital PCR, and also the ability to follow the subclonal evolution of tumors in a limited number of patients [10] . We confirm in an NSCLC population the high sensitivity of the InVision TM assay, matching (and in some cases exceeding) the sensitivity of plasma ddPCR. This high sensitivity, combined with accurate quantification and an ability to detect a full spectrum of genomic variants (something difficult to do with PCR assays), makes this NGS-based approach a compelling alternative to ddPCR for detection of T790M and other actionable mutations.
We also report for the first time the ability of a novel ampliconsequencing assay to detect gene fusions, with high sensitivity in cfDNA; the one missed ALK case was a patient with stage IIIB disease. In contrast, existing data on hybrid-capture NGS have suggested suboptimal sensitivity (54%) for the detection of EML4-ALK fusions [16] . Our team has also previously reported the detection of fusions genes (2/3 ALK, 2/3 RET, 2/2 ROS1) using a bias-corrected, targeted cfDNA NGS, detecting breakpoints and fusions partners using a single assay [7] . Further prospective evaluation is needed to clarify the potential sensitivity advantages of the different plasma NGS approaches for low AF mutations and the full spectrum of targetable fusions.
Though NGS of tumor tissue may be an imperfect reference standard in patients with drug resistance, our data nonetheless suggest compelling specificity with the InVision assay, which is reassuring given the plasma-positive, tumor-negative discordance seen at times with hybrid-capture NGS [6] . We identified four potential false positives-one we confirmed with plasma ddPCR, one is consistent with CHIP, and one we believe is likely due to subclonal resistance heterogeneity [14] . The only concerning false positive was a KRAS G12D mutation found at low AF (0.2%), which was not detectable with plasma ddPCR, but consistent with the patient's clinical presentation, and this case highlights the challenges of validating assays which are potentially more sensitive than established validated assays. Still, the lack of any false positives for EGFR driver mutations highlights that targetable mutations, even when found at a very low AF, can be considered actionable when found with a well validated assay.
Our data highlight the potential value of amplicon-based plasma NGS for characterizing treatment resistance in NSCLC. In patients treated with osimertinib, we could detect common mechanisms of resistance to EGFR-TKIs [2] , including expected point mutations, expected gene amplifications (MET, HER2), and a novel tertiary EGFR mutation (Q791P), which was cross-validated by another sequencing approach. Surprisingly, we found three low level KRAS mutations (one which was confirmed in tumor and has been reported previously), suggesting this may be a recurring mechanism of resistance to osimertinib. Serial plasma NGS also offers potential insights-for example in some cases with an incomplete response in the driver EGFR mutation (which has been suggested previously to indicate poorer treatment outcomes [17] ), we could detect early presence of a coexistent resistance mutation. The ability of plasma NGS to detect resistance mutations coexistent with T790M as well as detecting a range of tertiary EGFR mutations makes it a potentially powerful alternative to established PCR-based assays for resistance genotyping. Furthermore, the detection in a few cases (Figure 2 ) of resistance mutations at low AF that overgrow the T790M on osimertinib therapy supports the potential clinical value of such low AF resistance mutations, and deserves further study.
Conclusion
In conclusion, we demonstrate herein the ability of ampliconbased NGS to detect with a wide range of targetable genotypes in advanced NSCLC, including high accuracy for point mutations and indels, and compelling initial data for gene fusions and CNVs. This approach also permits early detection of resistance mechanisms during treatment, making it a potentially valuable tool to guide early modifications of targeted therapies. Amplicon-based plasma NGS has attractive sensitivity and specificity and deserves further study as an alternative to hybrid-capture approaches.
